ALNA News and Press, Allena Pharmaceuticals Inc. From 07/17/20

Gainers:  Verona Pharma (NASDAQ: VRNA )   +181% . More news on: Verona Pharma plc, RumbleON, Inc., Checkpoint Therapeutics, Inc., Stocks on the move, , Read more ...

NEWTON, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorde...

Secoo (NASDAQ: SECO ) +85%  as Qudian becomes largest shareholder. More news on: Secoo Holding Limited, Summit Wireless Technologies, Inc., RCM Technologies, Inc., Stocks on the move, , Read more ...

Westwater Resources (NASDAQ: WWR ) +144%  on positive independent test results on ULTRA-PMG. More news on: Westwater Resources, Inc., Tenax Therapeutics, Inc., BioHiTech Global, Inc., Stocks on the move, , Read more ...

Digital Ally (NASDAQ: DGLY ) +81%  as Body-camera, surveillance stocks surge pre-market after protests . More news on: Digital Ally, Inc., Allied Esports Entertainment Inc., CTI BioPharma Corp., Stocks on the move, , Read more ...

NEWTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, to...

Allena Pharmaceuticals ( ALNA ) Q1 results : Revenues: $0; Net loss: ($7.6M) (+33.3%); loss/share: ($0.31) (+43.6%); Quick Assets: $20.5M (-31.7%). More news on: Allena Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...

Allena Pharmaceuticals (NASDAQ: ALNA ): Q1 GAAP EPS of -$0.31 beats by $0.13 . More news on: Allena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

-- Revised URIROX-2 Trial Design to Potentially Reduce Size and Cost of Trial -- -- Finalized Protocol and Selected Contract Research Organization for Phase 1 Clinical Trial of ALLN-346 -- --  Presenting Late-Breaking Abstract on Kidney Stone Risk and Association with Urinary...

Allena Pharmaceuticals (NASDAQ: ALNA ): Q4 GAAP EPS of -$0.47 beats by $0.06 . More news on: Allena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...